Mild premorbid intellectual impairment as a resilience factor in Down syndrome associated Alzheimer's disease
Cognitive decline timing and slope differ depending on PII level, but AD biomarker pathology does not. If cognition is used for staging or endpoints in clinical trials, then PII should be considered.
Authors
- James Tyler Kennedy
Institutions
- Washington University in St. Louis (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_099392
- Primary Topic
- Down syndrome and intellectual disability research
- Type
- article
- Field-Weighted Citation Impact
- 0.00